Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Gubin, Matthew M. 1; Zhang, Xiuli 2; Schuster, Heiko 3; Caron, Etienne 4; Ward, Jeffrey P. 1,5; Noguchi, Takuro 1; Ivanova, Yulia 1; Hundal, Jasreet 6; Arthur, Cora D. 1; Krebber, Willem-Jan 7; Mulder, Gwenn E. 7; Toebes, Mireille 8; Vesely, Matthew D. 1; Lam, Samuel S. K. 1; Korman, Alan J. 9; Allison, James P. 10; Freeman, Gordon J. 11; Sharpe, Arlene H. 12; Pearce, Erika L. 1; Schumacher, Ton N. 8; Aebersold, Ruedi 4,13; Rammensee, Hans-Georg 3; Melief, Cornelis J. M. 7,14; Mardis, Elaine R. 6,15; Gillanders, William E. 2; Artyomov, Maxim N. 1; Schreiber, Robert D. 1,*
[Letter]
Nature.
515(7528):577-581, November 27, 2014.
(Format: HTML, PDF)